Reproductive Health · 1991
MRC Vitamin Study: Folic Acid Prevents Neural Tube Defect Recurrence
Medical Research Council Vitamin Study
Neural tube defects, principally spina bifida and anencephaly, were among the more common serious congenital malformations in the United Kingdom and North America in the mid-twentieth century. Affected pregnancies typically ended in termination after prenatal diagnosis, in stillbirth, or in the birth of a child with permanent disability. Women who had delivered one affected pregnancy faced recurrence risks of approximately 3-5%, well above the background population rate. Epidemiological data from the 1970s and 1980s had suggested an association between poor nutritional status, particularly low folate, and neural tube defect risk, but the evidence was largely observational and the mechanism incompletely understood.
Nicholas Wald, an epidemiologist with experience in antenatal screening, designed the Medical Research Council Vitamin Study to test periconceptional supplementation prospectively. The trial enrolled 1,817 women who had a previous pregnancy affected by a neural tube defect, a high-risk population chosen to maximize the statistical power to detect an effect. Participants were randomized to one of four groups: folic acid alone, a mixture of other vitamins, both together, or neither. Richard Schorah, a biochemist at Leeds with expertise in folate metabolism, contributed to the scientific design and laboratory analysis. Enrollment took place across multiple centers in the United Kingdom and several other countries.
The trial was stopped early in April 1991, when interim data crossed the pre-specified efficacy boundary. Women who received folic acid had a 72% lower recurrence risk compared to those who did not (relative risk 0.28, 95% CI 0.12-0.71). The other vitamins conferred no detectable benefit. The size of the effect was large by the standards of a nutritional intervention, and the stopping decision was made with the steering committee's judgment that continued allocation to the no-folate arms was no longer ethically justifiable. The results were published in the Lancet in July 1991.
Policy responses were swift. The U.S. Public Health Service recommended in 1992 that all women of childbearing age consume 400 micrograms of folic acid daily. A complementary randomized trial by Czeizel and Dudas in Hungary, published in 1992, showed that folic acid supplementation reduced primary occurrence of neural tube defects in women with no prior affected pregnancy. Together, the two trials established that the intervention worked in both primary and secondary prevention. The U.S. Food and Drug Administration mandated the addition of folic acid to enriched grain products beginning in January 1998.
After fortification began, the birth prevalence of neural tube defects in the United States fell by approximately 35%. Canada, Chile, and numerous other countries followed with mandatory fortification programs; countries without such programs have continued to document higher rates. The biochemical mechanism by which folate reduces neural tube defect risk involves its role as a methyl donor in single-carbon metabolism, but the precise developmental step protected by adequate folate at the time of neural tube closure around day 28 post-fertilization remains a subject of active investigation.
Key People
- Nicholas Wald — Epidemiologist who designed the MRC Vitamin Study and led its analysis
- Richard Schorah — Leeds biochemist and co-investigator who contributed folate metabolism expertise
- Andrew Czeizel — Hungarian geneticist whose complementary RCT confirmed primary prevention by folic acid
Lancet, 1991
Related landmarks
- 1992 · Czeizel & Dudas: Folic Acid Prevents First-Occurrence Neural Tube Defects (Reproductive Health)
- 1995 · Collaborative Eclampsia Trial: Magnesium Sulfate for Eclampsia (Reproductive Health)
- 1997 · Dolly the Cloned Sheep (Reproductive Health)
- 2002 · Magpie Trial: Magnesium Sulfate for Pre-eclampsia (Reproductive Health)